Interestingly, the exogenous upregulation of SOCS3 was capable of re-sensitizing recipient cells to gemcitabine which were already exposed to EVs derived from resistant NSCLC cells. This evidence concerns the gene SOCS3 and non-small cell lung carcinoma.